Amicus Therapeutics (NASDAQ:FOLD) Issues Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Amicus Therapeutics (NASDAQ:FOLDGet Rating) issued its quarterly earnings results on Thursday. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.02, Fidelity Earnings reports. Amicus Therapeutics had a negative return on equity of 91.37% and a negative net margin of 87.50%. During the same period in the previous year, the firm posted ($0.19) EPS. Amicus Therapeutics updated its FY 2022 guidance to EPS.

Amicus Therapeutics Stock Up 11.3 %

NASDAQ FOLD traded up $1.24 on Friday, hitting $12.18. 6,400,522 shares of the company’s stock were exchanged, compared to its average volume of 2,889,872. The company has a debt-to-equity ratio of 1.63, a quick ratio of 3.81 and a current ratio of 4.00. The firm’s 50-day moving average price is $9.95 and its two-hundred day moving average price is $9.02. Amicus Therapeutics has a fifty-two week low of $5.91 and a fifty-two week high of $12.69.

Analyst Upgrades and Downgrades

Separately, The Goldman Sachs Group assumed coverage on Amicus Therapeutics in a research report on Wednesday, April 13th. They issued a “neutral” rating on the stock. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $15.25.

Insiders Place Their Bets

In other Amicus Therapeutics news, CEO John F. Crowley sold 10,468 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $10.86, for a total transaction of $113,682.48. Following the transaction, the chief executive officer now owns 900,525 shares in the company, valued at approximately $9,779,701.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Amicus Therapeutics news, CEO John F. Crowley sold 21,814 shares of the business’s stock in a transaction that occurred on Monday, May 23rd. The stock was sold at an average price of $8.00, for a total transaction of $174,512.00. Following the transaction, the chief executive officer now owns 944,153 shares in the company, valued at approximately $7,553,224. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO John F. Crowley sold 10,468 shares of the business’s stock in a transaction that occurred on Friday, July 15th. The stock was sold at an average price of $10.86, for a total value of $113,682.48. Following the transaction, the chief executive officer now owns 900,525 shares in the company, valued at approximately $9,779,701.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 130,779 shares of company stock worth $1,237,966. Company insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

Several institutional investors have recently modified their holdings of FOLD. US Bancorp DE boosted its stake in shares of Amicus Therapeutics by 16,809.0% during the 1st quarter. US Bancorp DE now owns 15,049 shares of the biopharmaceutical company’s stock worth $143,000 after acquiring an additional 14,960 shares in the last quarter. MetLife Investment Management LLC boosted its stake in shares of Amicus Therapeutics by 53.3% during the 1st quarter. MetLife Investment Management LLC now owns 145,476 shares of the biopharmaceutical company’s stock worth $1,378,000 after acquiring an additional 50,600 shares in the last quarter. Mariner LLC boosted its stake in shares of Amicus Therapeutics by 15.5% during the 1st quarter. Mariner LLC now owns 26,338 shares of the biopharmaceutical company’s stock worth $249,000 after acquiring an additional 3,539 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in shares of Amicus Therapeutics by 2.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,004,734 shares of the biopharmaceutical company’s stock worth $18,985,000 after acquiring an additional 47,117 shares in the last quarter. Finally, UBS Group AG lifted its stake in Amicus Therapeutics by 7.7% in the 1st quarter. UBS Group AG now owns 512,442 shares of the biopharmaceutical company’s stock valued at $4,853,000 after buying an additional 36,572 shares in the last quarter.

Amicus Therapeutics Company Profile

(Get Rating)

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data.

Read More

Earnings History for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.